Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Drug Profile

Research programme: gene editing therapeutics - Intellia Therapeutics/Novartis

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Intellia Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 04 Aug 2016 Intellia Therapeutics announces intention to submit IND to US FDA in 2018
  • 07 Jan 2015 Novartis enters into collaboration and licensing agreements with Intellia Therapeutics and Caribou Biosciences relating to the application of CRISPR technology
  • 18 Nov 2014 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top